Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Safety and Effects of Englumafusp Alfa with Obinutuzumab and Glofitamab for Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of cancer called Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma, which is a condition where the cancer returns or does not respond to treatment. The study is testing a new treatment approach using a combination of medications. The main treatment being studied is called Englumafusp Alfa (also known by its code name RO7227166), which is a special type of protein designed to target cancer cells. This treatment is being tested in combination with two other medications, Obinutuzumab and Glofitamab. These medications are given through an intravenous (IV) infusion, which means they are administered directly into the bloodstream.

The purpose of the study is to evaluate the safety and effectiveness of these medications when used together. Participants in the study will receive a pre-treatment dose of Obinutuzumab before starting the combination therapy. The study will be conducted in different phases to determine the best dose and to observe how the body processes the medications. The study will also look at how well the treatment works in reducing the size of the tumors and controlling the disease.

Throughout the study, participants will be closely monitored for any side effects and how their bodies respond to the treatment. The study aims to find the most effective dose that can be safely given to patients. This research is important for developing new treatment options for people with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma and potentially improving their outcomes. The study is expected to continue until 2026, with the goal of gathering comprehensive data on the treatment's safety and effectiveness.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial treatment

    Receive a pre-treatment dose of obinutuzumab through an intravenous (IV) infusion. This is a solution administered directly into the bloodstream.

    This step is designed to prepare the body for the subsequent treatments.

  2. Step 2

    Combination therapy phase I/II

    Participate in a dose-escalation study to determine the appropriate dose of englumafusp alfa in combination with obinutuzumab and glofitamab.

    Receive these medications through IV infusions. The goal is to find the maximum tolerated dose and evaluate safety and tolerability.

    This phase is for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma.

  3. Step 3

    Combination therapy phase III

    Participate in a dose-expansion study to assess the anti-tumor activity of englumafusp alfa in combination with glofitamab.

    Receive these medications through IV infusions. This phase aims to compare the effectiveness of the combination therapy against glofitamab alone.

    This phase is for patients with large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma.

  4. Step 4

    Monitoring and assessment

    Undergo regular assessments to monitor the response to treatment, including imaging tests like FDG-PET/CT scans.

    Evaluate the nature and frequency of any side effects or adverse events experienced during the trial.

    Assess overall response rate, disease control rate, and progression-free survival.

  5. Step 5

    Completion and follow-up

    Complete the trial by the estimated end date of March 31, 2026.

    Participate in follow-up assessments to monitor long-term effects and overall survival.

Who can join the trial?

6 criteria

  • Must be willing and able to stay in the hospital as required by the study and follow all study-related procedures.
  • Must have a history or current status of a blood cancer that is confirmed by a test and is expected to show certain proteins called CD19 and CD20. The cancer must have come back or not responded to at least one previous treatment, and there should be no other treatment options expected to help extend life.
  • Must have at least one tumor that can be measured and is at least 1.5 cm in size, as seen on a CT scan.
  • Must be able and willing to provide a new tissue sample from a safe area, if there is more than one measurable tumor. If a new sample cannot be provided, the most recent tissue sample from the past 6 months should be given, if possible. The sample should not be affected by major events. The preferred sample type is a block of tissue preserved in a special way, but if not available, unstained slides are acceptable.
  • Must have a performance status of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG) scale, which means being fully active or having some symptoms but being able to carry out light work.
  • Must have a life expectancy of at least 12 weeks.

Who cannot join the trial?

10 criteria

  • Patients who have a different type of cancer than the one being studied.
  • Patients who have not experienced a return or worsening of their B-cell Non-Hodgkin's Lymphoma.
  • Patients who are not within the specified age range for the study.
  • Patients who are not able to follow the study procedures or instructions.
  • Patients who have other serious health conditions that could interfere with the study.
  • Patients who are pregnant or breastfeeding.
  • Patients who have participated in another clinical trial recently.
  • Patients who have allergies to the study medications.
  • Patients who have received certain treatments that are not allowed in the study.
  • Patients who have infections that are not well controlled.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Englumafusp Alfa (RO7227166)

    is an experimental medication being studied for its potential to treat certain types of lymphoma. It is designed to target a protein called CD19, which is found on the surface of some cancer cells. By binding to this protein, Englumafusp Alfa may help the immune system recognize and attack the cancer cells more effectively.

  • Obinutuzumab

    is a medication used to treat certain types of blood cancers, including non-Hodgkin's lymphoma. It works by targeting a protein called CD20 on the surface of cancer cells, helping the immune system to destroy these cells. In this trial, Obinutuzumab is used both as a pre-treatment and in combination with other therapies to enhance their effectiveness.

  • Glofitamab

    is another investigational drug being tested for its ability to treat lymphoma. It is designed to engage the immune system to target and kill cancer cells. Glofitamab is being studied both as a standalone treatment and in combination with Englumafusp Alfa to assess its potential benefits in treating various types of lymphoma.

What is already known about the treatment

  • Englumafusp Alfa

    Englumafusp Alfa is administered intravenously and is currently being studied in clinical trials for its potential use in treating relapsed or refractory B-cell Non-Hodgkin’s Lymphoma. It is designed to target CD19, a protein found on the surface of B-cells, and activate the 4-1BB receptor, which can enhance the immune system's ability to attack cancer cells. This medication is classified as an immunotherapy agent, specifically a bispecific antibody, and is being evaluated for its safety, tolerability, and anti-tumor activity in combination with other treatments.

  • Obinutuzumab

    Obinutuzumab is administered intravenously and is an established medication used in the treatment of certain types of B-cell Non-Hodgkin’s Lymphoma. It works by targeting the CD20 protein on the surface of B-cells, leading to the destruction of these cancerous cells. Obinutuzumab is classified as a monoclonal antibody and is often used in combination with other therapies to enhance its effectiveness in treating lymphoma.

  • Glofitamab

    Glofitamab is administered intravenously and is currently under investigation in clinical trials for its potential to treat relapsed or refractory B-cell Non-Hodgkin’s Lymphoma. It functions by binding to both CD20 on B-cells and CD3 on T-cells, thereby directing the immune system to attack the cancerous B-cells. Glofitamab is classified as a bispecific antibody and is being studied for its ability to improve outcomes when used alone or in combination with other treatments.

Investigated diseases

Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma – This is a type of cancer that originates in the lymphatic system, specifically affecting B-cells, which are a type of white blood cell. The term "relapsed" refers to the return of the disease after treatment, while "refractory" indicates that the disease does not respond to treatment. It typically presents with symptoms such as swollen lymph nodes, fever, night sweats, and weight loss. The disease can progress by spreading to other parts of the lymphatic system or organs. It is characterized by the uncontrolled growth of abnormal B-cells, which can impair the immune system's ability to fight infections. The progression of the disease can vary, with some cases advancing slowly and others more rapidly.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase ITrial ID2022-502616-37-00Protocol codeBP41072Estimated enrolment351 patientsSponsorF. Hoffmann-La Roche AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.